Assay Service request for assessing select required DMPK properties of potential therapeutic compounds generated in SMC

The National Institutes of Health (NIH) seeks a qualified vendor to provide orthogonal assay development and laboratory testing services for drug metabolism and pharmacokinetics (DMPK) evaluation of novel therapeutic compounds. The work includes in‑vitro assays (Caco‑2 permeability, plasma protein binding, hepatic metabolic stability) and an in‑vivo pharmacokinetic study in C57BL/6 mice. All assays must be performed under a single‑vendor arrangement for consistency and cost‑effectiveness, with a performance period of one year from award. The contract will be firm‑fixed‑price, evaluated on technical merit and price, with technical factors weighted more heavily. • Conduct Caco‑2 permeability, plasma protein binding, and hepatic metabolic stability assays. • Perform a full pharmacokinetic study in C57BL/6 mice. • Deliver assay data and reports to support SAR optimization for metabolic and alcohol‑use disorder therapeutics. • Provide pricing, delivery schedule, and FOB details in the proposal. • Must be registered in SAM and include UEI, TIN, and size certification.